Table 3.

Adverse events.

Adverse events	Frequency	≥ Grade2	Dose adjustment	≥ Grade3	Dose adjustment
Fatigue	88.7% (55/62)	0	0	0	0
Dizziness	3.2% (2/62)	0	0	0	0
Numbness in the hands and feet	1.6% (1/62)	0	0	0	0
Hypertension	71.0% (44/62)	8	2 (anlotinib 10 mg)	1	Terminate
Pruritus	37.1% (23/62)	0	0	0	0
Thyroid dysfunction	21.0% (13/62)	0	0	0	0
Pneumonia	1.6% (1/62)	1	0	0	0
Fever	0	0	0	0	0
Leukopenia	33.9% (21/62)	1	0	0	0
Neutropenia	1.6% (1/62)	0	0	0	0
Thrombocytopenia	9.7% (6/62)	0	0	2	2 (1 delayed anlotinib to 10 mg and 1 delayed anlotinib dosage to 8 mg)
Proteinuria	17.7% (11/62)	4	1 (anlotinib 10 mg)	4	4 (3 delayed anlotinib dose to 10 mg and 1 delayed anlotinib dose to 8 mg)
Nausea	12.9% (8/62)	0	0	0	0
Abdominal distention	6.5% (4/62)	0	0	0	0
Abdominal pain	4.8% (3/62)	0	0	0	0
Diarrhea	12.9% (8/62)	0	0	0	0
Vomiting	8.1% (5/62)	0	0	0	0
Constipation	6.5% (4/62)	0	0	0	0
AST increased	14.5% (9/62)	2	0	0	0
ALT increased	17.7% (11/62)	2	0	0	0
Blood bilirubin increased	6.5% (4/62)	0	0	0	0
Amylase increase	12.9% (8/62)	0	0	0	0

Adverse events were classified according to the National Cancer Institute Common Terminology Criteria (CTCAE) version 5.0.

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase.